Rilutek(riluzole)
Exservan, Rilutek, Tiglutik (riluzole) is a small molecule pharmaceutical. Riluzole was first approved as Rilutek on 1995-12-12. It is used to treat amyotrophic lateral sclerosis in the USA. It has been approved in Europe to treat amyotrophic lateral sclerosis. It is known to target potassium channel subfamily K member 4, intermediate conductance calcium-activated potassium channel protein 4, potassium channel subfamily K member 2, potassium voltage-gated channel subfamily H member 2, short transient receptor potential channel 5, small conductance calcium-activated potassium channel protein 3, potassium voltage-gated channel subfamily D member 2, small conductance calcium-activated potassium channel protein 1, small conductance calcium-activated potassium channel protein 2, potassium voltage-gated channel subfamily D member 3, and calmodulin-1.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Exservan, Rilutek, Tiglutik (generic drugs available since 2003-01-29)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| amyotrophic lateral sclerosis | EFO_0000253 | D000690 | G12.21 |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
67 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | 3 | 12 | 7 | 1 | 2 | 20 |
| Inflammation | D007249 | — | — | — | 1 | — | 1 | ||
| Fatigue | D005221 | HP_0012378 | R53.83 | — | — | — | 1 | — | 1 |
| Tourette syndrome | D005879 | EFO_0004895 | F95.2 | — | — | — | 1 | — | 1 |
| Fragile x syndrome | D005600 | Q99.2 | — | — | — | 1 | — | 1 | |
| Memory disorders | D008569 | — | — | — | 1 | — | 1 | ||
| Affect | D000339 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Spinal cord injuries | D013119 | EFO_1001919 | — | 2 | 1 | — | 1 | 3 | |
| Cerebellar ataxia | D002524 | — | 2 | 1 | — | — | 2 | ||
| Spinocerebellar ataxias | D020754 | — | — | 1 | — | — | 1 | ||
| Neuromuscular diseases | D009468 | EFO_1001902 | G70.9 | — | 1 | 1 | — | — | 1 |
| Social phobia | D000072861 | EFO_1001917 | F40.1 | — | 1 | 1 | — | — | 1 |
| Performance anxiety | D060805 | — | 1 | 1 | — | — | 1 | ||
| Huntington disease | D006816 | G10 | — | — | 1 | — | — | 1 | |
| Multiple system atrophy | D019578 | — | — | 1 | — | — | 1 | ||
| Progressive supranuclear palsy | D013494 | EFO_0002512 | G23.1 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | 3 | — | — | 1 | 4 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | 3 | 1 | — | — | — | 3 |
| Autism spectrum disorder | D000067877 | F84.0 | 1 | 2 | — | — | — | 3 | |
| Melanoma | D008545 | 2 | 1 | — | — | — | 3 | ||
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 2 | — | — | — | 2 |
| Depression | D003863 | F33.9 | — | 2 | — | — | — | 2 | |
| Obsessive-compulsive disorder | D009771 | EFO_0004242 | F42 | — | 2 | — | — | — | 2 |
| Chronic progressive multiple sclerosis | D020528 | — | 1 | — | — | — | 1 | ||
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 1 | — | — | — | 1 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 1 | — | — | — | 1 |
Show 6 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | RILUZOLE |
| INN | riluzole |
| Description | Riluzole is a member of benzothiazoles. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Nc1nc2ccc(OC(F)(F)F)cc2s1 |
Target
Agency Approved
No data
Alternate
KCNK4
KCNK4
KCNN4
KCNN4
KCNK2
KCNK2
KCNH2
KCNH2
TRPC5
TRPC5
KCNN3
KCNN3
KCND2
KCND2
KCNN1
KCNN1
KCNN2
KCNN2
KCND3
KCND3
CALM1
CALM1
Organism
Homo sapiens
Gene name
KCNK4
Gene synonyms
TRAAK
NCBI Gene ID
Protein name
potassium channel subfamily K member 4
Protein synonyms
K2P4.1 potassium channel, potassium channel, subfamily K, member 4, potassium channel, two pore domain subfamily K, member 4, TRAAK, TWIK-related arachidonic acid-stimulated potassium channel protein, Two pore K(+) channel KT4.1, two pore K+ channel KT4.1, Two pore potassium channel KT4.1
Uniprot ID
Mouse ortholog
Kcnk4 (16528)
potassium channel subfamily K member 4 (O88454)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,155 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
8,266 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more